"Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
| Descriptor ID |
D004791
|
| MeSH Number(s) |
D27.505.519.389
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Enzyme Inhibitors".
This graph shows the total number of publications written about "Enzyme Inhibitors" by people in this website by year, and whether "Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 6 | 2 | 8 |
| 1996 | 5 | 9 | 14 |
| 1997 | 5 | 13 | 18 |
| 1998 | 4 | 8 | 12 |
| 1999 | 9 | 16 | 25 |
| 2000 | 6 | 12 | 18 |
| 2001 | 8 | 16 | 24 |
| 2002 | 6 | 29 | 35 |
| 2003 | 9 | 21 | 30 |
| 2004 | 5 | 20 | 25 |
| 2005 | 7 | 19 | 26 |
| 2006 | 9 | 14 | 23 |
| 2007 | 11 | 15 | 26 |
| 2008 | 4 | 18 | 22 |
| 2009 | 5 | 14 | 19 |
| 2010 | 6 | 8 | 14 |
| 2011 | 4 | 1 | 5 |
| 2012 | 6 | 11 | 17 |
| 2013 | 4 | 5 | 9 |
| 2014 | 8 | 8 | 16 |
| 2015 | 11 | 7 | 18 |
| 2016 | 8 | 3 | 11 |
| 2017 | 9 | 8 | 17 |
| 2018 | 2 | 6 | 8 |
| 2019 | 2 | 2 | 4 |
| 2020 | 3 | 4 | 7 |
| 2021 | 5 | 2 | 7 |
| 2022 | 1 | 4 | 5 |
| 2023 | 2 | 2 | 4 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Enzyme Inhibitors" by people in Profiles.
-
Role of the Mobile Active Site Flap in IMP Dehydrogenase Inhibitor Binding. ACS Infect Dis. 2025 Feb 14; 11(2):442-452.
-
Inhibition of nitric oxide synthase transforms carotid occlusion-mediated benign oligemia into de novo large cerebral infarction. Theranostics. 2025; 15(2):585-604.
-
Quinoline-based compounds can inhibit diverse enzymes that act on DNA. Cell Chem Biol. 2024 Dec 19; 31(12):2112-2127.e6.
-
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors? Neuro Oncol. 2024 Oct 03; 26(10):1805-1822.
-
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses. Nat Cancer. 2024 Oct; 5(10):1515-1533.
-
Enolase inhibitors as therapeutic leads for Naegleria fowleri infection. PLoS Pathog. 2024 Aug; 20(8):e1012412.
-
Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia. Expert Rev Hematol. 2024 Jun; 17(6):211-221.
-
Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer. Prostate. 2024 Mar; 84(4):349-357.
-
DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia. Blood Adv. 2023 11 14; 7(21):6685-6701.
-
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Science. 2023 09 08; 381(6662):eabn4180.